Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
AVONEX® Combination Trial - "ACT"
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2008-05-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 350
- Registration Number
- NCT00112034
- Locations
- 🇺🇸
MS Academic Coordinating Center, Cleveland, Ohio, United States
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
- Conditions
- Colorectal CarcinomaMetastases
- First Posted Date
- 2005-04-12
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 44
- Registration Number
- NCT00107861
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
- Conditions
- Tumors
- First Posted Date
- 2005-03-09
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 13
- Registration Number
- NCT00105170
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2005-02-11
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 31
- Registration Number
- NCT00103558
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
- Conditions
- MetastasesColorectal Cancer
- First Posted Date
- 2005-01-20
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT00102024
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT00099489
- Locations
- 🇺🇸
Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
🇺🇸Neuromuscular Research Center, Scottsdale, Arizona, United States
🇺🇸University of Florida, Jacksonville, Jacksonville, Florida, United States
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 110
- Registration Number
- NCT00097760
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2009-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 168
- Registration Number
- NCT00090038
- Locations
- 🇺🇸
USC KECK School of Medicine, Los Angeles, California, United States
🇺🇸Radiant Research, Honolulu, Hawaii, United States
🇺🇸Carle Clinic Association, Urbana, Illinois, United States
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 299
- Registration Number
- NCT00083759
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Clinical Research Unit / University of Arizona, Tucson, Arizona, United States
🇺🇸Arthritis Medical Clinic of North County, Inc., Escondido, California, United States
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 462
- Registration Number
- NCT00078611
- Locations
- 🇺🇸
Harmony Clinical Research, Oro Valley, Arizona, United States
🇺🇸Advanced Clinical Therapeutics, Tucson, Arizona, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States